The 5 references in paper A. Petrov M., I. Stolyarov D., T. Gorokhova V., А. Петров М., И. Столяров Д., Т. Горохова В. (2015) “ТЕРИФЛУНОМИД В ТЕРАПИИ РЕМИТТИРУЮЩЕГО РАССЕЯННОГО СКЛЕРОЗА: ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ // TERIFLUNOMIDE IN TREATMENT OF REMITTING-RELAPSING MULTIPLE SCLEROSIS: EFFICACY AND SAFETY” / spz:neicon:nevro:y:2013:i:2:p:48-51

1
Сherwinski H.M., Cohn R.G., Cheung P. et al. The immunosuppressant lefl unomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. 1995;
(check this in PDF content)
2
5(2): 1043—9. 2. Confavreux C., Li D.K., Freedman M.S. Long-term follow-up of a phase 2 study of oral terifl unomide in relapsing multiple sclerosis: safety and effi cacy results up to 8.5 years. Multiple Scler.2012; 18(9): 1278—89.
(check this in PDF content)
3
Elder R.T., Xu X., Williams J.W. et al. The immunosuppressive metabolite of lefl unomide, A77 1726, affects murine T-cells through two biochemical mechanisms. J. Immunol. 1997; 159: 22—7.
(check this in PDF content)
4
Freedman M.S., Wolynsky J.S., Frangin G.A. et al Oral teriflnomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: safety and effi cacy results. Presented at the Annual Meeting of the American Academy of Neurology (AAN); April 14, 2010; Toronto.
(check this in PDF content)
5
Freedman M.S., Wolinsky J.S., Wamil B. et al Terifl unomide added to interferon beta in relapsing multiple sclerosis. Neurology 2012; 78: 1877—85.
(check this in PDF content)